Skip Navigation
Toggle Navigation
Search:
Search Submit
About
Our Company
Executive Team
Partners
Our Culture
Programs
Pipeline
Scientific Presentations
Clinical Trials
Expanded Access Policy
News
Press Releases
Careers
Who We Are
Job Opportunities
Contact Us
Programs
Scientific Presentations
09.09.2022
Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Mutant Inhibitor with Activity Against Classical and Atypical EGFR Mutations
03.08.2022
FURLONG: Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study
09.16.2021
Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
